Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Advanced Medical Solutions Group plc (AMS.L)
Winsford, GB
Advanced Medical Solutions Group plc (AMS), along with its subsidiaries, specializes in the innovation, production, and worldwide distribution of advanced medical solutions. Its primary markets include wound treatment, surgical procedures, and wound closure, with a significant presence across the United Kingdom, Germany, France, wider Europe, the United States, and other international regions. The company's operations are structured into two main divisions: Surgical and Woundcare. The Surgical segment provides a comprehensive range of specialized products. These include topical tissue adhesives for sealing and closing wounds, offered under the LiquiBand brand; sutures and collagen-derived materials for surgical and dental applications, marketed as RESORBA; various collagen products; the LiquiBand Fix8 laparoscopic device designed for internally securing hernia meshes; and internal sealants available under the Seal-G and Seal-G MIST brands. Conversely, the Woundcare segment focuses on a broad spectrum of sophisticated wound management technologies. Its offerings comprise alginates, medical foams, films, fibers, hydrogels, antimicrobial dressings, and hydrocolloids, alongside a dedicated line of wound care products under the ActivHeal brand. Established in 1991, Advanced Medical Solutions Group plc maintains its corporate headquarters in Winsford, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.45% | -3.10% | -9.88% | +2.10% | +0.23% | +0.46% | +10.83% | -1.79% | -21.79% | +9.91% | +1,157.18% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 6 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+29.0% ★ Q4'25: +87.2% (vs Q4'23)
-
EPS growth Medical - Instruments & Supplies: +16.3%+39.1% ★ Q4'25: -47.0% (vs Q4'23)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+5.7% Q4'25: +9.3% (vs Q4'23)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+9.6% Q4'25: +9.8% (vs Q4'23)
-
ROIC Medical - Instruments & Supplies: +6.0%+4.1% Q4'25: +8.6% (vs Q4'23)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.8% Q4'25: +1.5% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×1.88× Q4'25: 0.91× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 4 EPS Ana. |
Dec 2027 7 Rev. Ana. 5 EPS Ana. |
Dec 2028 6 Rev. Ana. 2 EPS Ana. |
Dec 2029 5 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
31.88M
est: 30.87M (+3.3%)
|
34.35M
est: 35.65M (-3.6%)
|
52.59M
est: 53.54M (-1.8%)
|
59.50M
est: 58.50M (+1.7%)
|
63.01M
est: 64.08M (-1.7%)
|
68.60M
est: 68.55M (+0.1%)
|
83.24M
est: 80.38M (+3.6%)
|
96.91M
est: 93.87M (+3.2%)
|
102.60M
est: 101.59M (+1.0%)
|
102.37M
est: 103.36M (-1.0%)
|
86.80M
est: 86.50M (+0.3%)
|
108.60M
est: 109.81M (-1.1%)
|
124.33M
est: 121.10M (+2.7%)
|
126.21M
est: 131.11M (-3.7%)
|
177.52M
est: 177.53M (0.0%)
|
228.94M
est: 228.80M (+0.1%)
|
245.76M
242.97M – 247.67M
+7.4% YoY
|
263.94M
257.12M – 268.66M
+7.4% YoY
|
285.83M
285.76M – 285.90M
+8.3% YoY
|
308.28M
302.47M – 312.30M
+7.9% YoY
|
| EBITDA |
5.74M
est: 4.20M (+36.5%)
|
6.05M
est: 6.57M (-8.0%)
|
13.79M
est: 9.00M (+53.3%)
|
15.91M
est: 13.55M (+17.4%)
|
17.31M
est: 16.52M (+4.8%)
|
19.15M
est: 19.25M (-0.5%)
|
22.12M
est: 23.41M (-5.5%)
|
28.22M
est: 25.83M (+9.2%)
|
32.93M
est: 30.61M (+7.6%)
|
30.12M
est: 32.84M (-8.3%)
|
17.53M
est: 25.47M (-31.2%)
|
31.55M
est: 31.22M (+1.1%)
|
34.94M
est: 33.57M (+4.1%)
|
31.40M
est: 30.86M (+1.7%)
|
29.68M
est: 41.90M (-29.2%)
|
43.39M
est: 53.86M (-19.4%)
|
57.85M
57.20M – 58.30M
+7.4% YoY
|
62.13M
60.53M – 63.24M
+7.4% YoY
|
67.29M
67.27M – 67.30M
+8.3% YoY
|
72.57M
71.20M – 73.52M
+7.9% YoY
|
| EBIT |
4.43M
est: 2.99M (+47.8%)
|
4.67M
est: 4.97M (-6.0%)
|
11.49M
est: 6.91M (+66.3%)
|
13.73M
est: 12.56M (+9.2%)
|
15.17M
est: 15.01M (+1.1%)
|
17.04M
est: 16.26M (+4.8%)
|
19.47M
est: 20.19M (-3.6%)
|
25.24M
est: 22.42M (+12.6%)
|
28.69M
est: 27.30M (+5.1%)
|
24.70M
est: 29.00M (-14.8%)
|
10.70M
est: 20.70M (-48.3%)
|
22.70M
est: 25.37M (-10.5%)
|
26.07M
est: 27.29M (-4.5%)
|
20.61M
est: 19.76M (+4.3%)
|
13.38M
est: 26.83M (-50.1%)
|
21.99M
est: 34.49M (-36.2%)
|
37.04M
36.62M – 37.33M
+7.4% YoY
|
39.78M
38.76M – 40.49M
+7.4% YoY
|
43.08M
43.07M – 43.09M
+8.3% YoY
|
46.47M
45.59M – 47.07M
+7.9% YoY
|
| Net Income |
4.83M
est: 3.49M (+38.4%)
|
4.85M
est: 5.54M (-12.5%)
|
9.69M
est: 7.36M (+31.7%)
|
11.37M
est: 10.60M (+7.2%)
|
12.86M
est: 12.49M (+3.0%)
|
14.12M
est: 13.79M (+2.4%)
|
15.69M
est: 16.72M (-6.2%)
|
20.13M
est: 18.42M (+9.3%)
|
22.65M
est: 21.78M (+4.0%)
|
18.92M
est: 22.90M (-17.4%)
|
8.58M
est: 16.15M (-46.9%)
|
17.48M
est: 19.80M (-11.7%)
|
20.41M
est: 19.67M (+3.7%)
|
15.89M
est: 11.37M (+39.7%)
|
7.09M
est: 23.90M (-70.3%)
|
9.95M
est: 22.28M (-55.3%)
|
25.61M
21.15M – 30.07M
+14.9% YoY
|
32.40M
26.24M – 38.55M
+26.5% YoY
|
45.46M
39.48M – 51.44M
+40.3% YoY
|
55.35M
53.99M – 56.29M
+21.8% YoY
|
| SGA |
307.0K
est: 9.98M (-96.9%)
|
314.0K
est: 11.09M (-97.2%)
|
17.50M
est: 15.02M (+16.5%)
|
20.82M
est: 18.14M (+14.8%)
|
20.92M
est: 22.78M (-8.2%)
|
23.46M
est: 22.42M (+4.6%)
|
28.58M
est: 27.78M (+2.9%)
|
33.31M
est: 33.55M (-0.7%)
|
34.63M
est: 36.04M (-3.9%)
|
35.56M
est: 35.27M (+0.8%)
|
34.73M
est: 30.37M (+14.4%)
|
38.45M
est: 37.22M (+3.3%)
|
49.00M
est: 40.03M (+22.4%)
|
52.19M
est: 49.73M (+5.0%)
|
67.08M
est: 67.51M (-0.6%)
|
81.68M
est: 86.78M (-5.9%)
|
93.21M
92.15M – 93.94M
+7.4% YoY
|
100.10M
97.52M – 101.89M
+7.4% YoY
|
108.41M
108.38M – 108.43M
+8.3% YoY
|
116.92M
114.72M – 118.44M
+7.9% YoY
|
| EPS |
0.03
est: 0.04 (-10.2%)
|
0.03
est: 0.04 (-25.6%)
|
0.05
est: 0.05 (-6.9%)
|
0.06
est: 0.06 (-1.7%)
|
0.06
est: 0.06 (-0.4%)
|
0.07
est: 0.07 (+2.3%)
|
0.07
est: 0.07 (-0.1%)
|
0.10
est: 0.09 (+4.0%)
|
0.11
est: 0.10 (+8.7%)
|
0.09
est: 0.10 (-8.6%)
|
0.04
est: 0.05 (-18.0%)
|
0.08
est: 0.09 (-11.9%)
|
0.09
est: 0.10 (-8.6%)
|
0.07
est: 0.05 (+41.8%)
|
0.03
est: 0.11 (-69.6%)
|
0.05
est: 0.11 (-59.5%)
|
0.13
0.10 – 0.14
+12.9% YoY
|
0.16
0.12 – 0.18
+25.6% YoY
|
0.21
0.18 – 0.23
+27.8% YoY
|
0.25
0.25 – 0.26
+21.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-05 | B | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-01 | B | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 5/5 | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 5/5 | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Amundi MSCI UK IMI SRI Climate Paris Aligned UCITS ETF DR - GBP (C) FT1K.L | 0.91% | 1.76M | 0.18% |
| 2 | Amundi MSCI UK IMI SRI Climate Paris Aligned UCITS ETF DR - EUR (C) C1U.PA | 0.91% | 1.76M | 0.18% |
| 3 | WisdomTree UK Quality Dividend Growth UCITS ETF - GBP UGRW.L | 0.56% | 61.4K | 0.29% |
| 4 | Amundi Prime UK Mid & Small Cap UCITS ETF DR - GBP (D) PRUK.L | 0.33% | 1.43M | 0.05% |
| 5 | iShares MSCI United Kingdom Small-Cap ETF EWUS | 0.17% | 70.2K | 0.59% |
| 6 | iShares MSCI UK Small Cap UCITS ETF CUKS.L | 0.17% | 219.0K | 0.58% |
| 7 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.10% | 345.9K | 0.23% |
| 8 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.10% | 345.9K | 0.23% |
| 9 | WisdomTree Europe SmallCap Dividend UCITS ETF Acc DFEA.L | 0.08% | 74.7K | 0.38% |
| 10 | WisdomTree Europe SmallCap Dividend UCITS ETF WTES.DE | 0.08% | 74.7K | 0.38% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Andrew Christopher Meredith | Chief Executive Officer & Executive Director | 619.0K | male |
| Edward Johnson | Chief Financial Officer, ESG Lead & Executive Director | 381.0K | male |
| Michael Edward King | Investor Relations Manager | — | male |
| Owen Bromley | Company Secretary | — | male |
| Ross McDonald | Chief Commercial Officer | — | male |
| Alexandra Dietrich | Chief Operations Officer | — | — |
| Simon Swain | Head of Legal | — | — |
| Cathy Tomlinson | Chief People Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AMS.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
